Remove 2023 Remove Patients Remove Pharmacology
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. 1,2 In the EU, an estimated 2.7

Patients 105
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience.

Medicine 102
article thumbnail

New radiopharmaceutical laboratory opens in Germany

European Pharmaceutical Review

The facility will also have capacity to conduct non-clinical pharmacology studies for detailed characterisation of its first-in-class development candidates, according to Ariceum. Internet] European Pharmaceutical Review, Issue 3 2023. 1 References Jaafar-Thiel. Meeting rising demands of a new radiotheranostic era. cited 2024Mar].

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023.

FDA 78
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

In this exclusive webinar, Dr. Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.

article thumbnail

NICE backs use of Boehringer’s Ofev in IPF from diagnosis

pharmaphorum

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE. The NHS should make Ofev available within 90 days of the announcement by NICE, which means in mid-March 2023.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). billion across the 7MM up to 2032, GlobalData’s predicted in a report published in December 2023.